# Project-001

> **NIH NIH P01** · WASHINGTON UNIVERSITY · 2020 · $518,398

## Abstract

Project 1 explores the transition from asymptomatic, preclinical Alzheimer disease (AD) to symptomatic AD by
incorporating the novel tau imaging tracer, T807 F18 (AV1451), into the biomarker-rich protocol of the Adult
Children Study (ACS) to identify the temporal onset of neocortical involvement by tau and to quantify tau
density and distribution. Project 1 findings will be correlated with other indicators of preclinical AD obtained in
all Projects and relevant Cores of this application as described in the Specific Aims below.
1. Assess cerebral tau distribution and burden in the ACS, at baseline and longitudinally every three years
thereafter, with T807 positron emission tomography (PET) imaging.
a. Compare tau burden cross-sectionally in cognitively normal participants and those with symptomatic AD.
b. Correlate cerebrospinal fluid (CSF) tau and p-tau181 (Biomarker Core, Project 2) with T807 to test the
hypothesis: tauopathy-related neural injury predicts the transition from preclinical to symptomatic
AD.
c. Similarly, correlate the spatial distribution of tauopathy to test the hypothesis: the spread of tauopathy
from the transentorhinal region to the neocortex predicts the transition from preclinical to
symptomatic AD.
2. Correlate cross-sectional and longitudinal T807 imaging:
a. With amyloid PET imaging (Project 4) to test the hypothesis that cerebral amyloidosis and tauopathy
each are necessary to predict the transition to symptomatic AD.
b. With CSF concentrations of tau, p-tau181, VILIP-1, SNAP-25, and Neurogranin (Biomarker Core, Project
2), as markers of synaptic and neural injury, and with CSF Aβ42 and YKL-40.
c. With imaging measures of hippocampal atrophy, reduced cortical thickness, and disrupted resting state
networks (Project 4) as markers of neural injury
3. Identify inflection points (changepoints) on composite measures of episodic memory (Clinical Core),
attentional control (Project 3), and global cognitive performance (Clinical Core) that indicate the cognitive
decline heralding the onset of symptomatic AD.

## Key facts

- **NIH application ID:** 9963097
- **Project number:** 5P01AG026276-15
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** JOHN MORRIS
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $518,398
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9963097

## Citation

> US National Institutes of Health, RePORTER application 9963097, Project-001 (5P01AG026276-15). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/9963097. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*